US EditionOneChain Immunotherapeutics announces Board of Directors appointment
Summary by European Pharmaceutical Manufacturer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
OneChain Immunotherapeutics announces Board of Directors appointment
OneChain Immunotherapeutics (OCI), a clinical-stage biotech company focused on the development of CAR-T therapies for the treatment of oncologic diseases, has announced the appointment of Barbara Krebs-Pohl as the new chair of the Board of Directors.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
